New Research has looked into a comprehensive and structured approach to genetic testing, matching child and young people with cancer to targeted treatments. The Study Aimed to Advance Precision Medicine in the UK to Help Young Cancer Patients Receive more targeted cancer treatments, an important step towards increasing survival rates and Reductions of trees.

Researchers LOKED At Tumors of Relapsed Childhood Cancers to see how they adapt and change in response to treatment. Researchers showed that a ctdna blood test, a less invasive approach to track tumor evolution, can add valuable information and, in some patients, detect additional dna mutations in the tumor that wasor Biopsy. The paper is Published Cancer discovery,

The first phase of the stratified medicine paediatrics (SMPAEDS1) Program is Advanceing Precision Medicine in the UK to Help Young Cancer Patients Receive more targeted and Lessic Treatments.

SMPAEDS1 Aimed to Advance Precision Medicine for Children and Young People with Cancer Has Returned. The project focused on Analyzing Childhood Cancer Tumors at Diagnosis and Relapse Stages of the Cancer Journey, to help better undersrstand how the tumors evolve.

The research team from the institute of Cancer Research, London Introduced The Use of CTDNA – DNA that is released into the bloodstream Circulation by Cancer Cancer Cells – Aas a Potancial tool for Tracing Cancer Program Identifying new treatment targets. The Ctdna Test offers a Less Invasive Way to Monitor How Tumor Mutations Change Over Time and Can Add Additional Information that that is Complimentary to Tissue Biopsy.

The first phase of the precision medicine research project was completed in October 2023 and was lead by, Professor Louis Chesler, Professor of Paidiatric Cancer Biology at the Institute of Cancer Reserch, London, Lon Consultant in Paediatric Oncology at the Royal Marsden NHS Foundation Trust, Together with Author, Dr. Sally george, group leader of the developmental oncology group at the institute of cancer research, longon and an honorary consultant paidiatric oncologist at the royal marsden 11.

Dr. George explains, “We showed that ctdna analysis can add Valuable information and that in some patients it can detect additional dna mutations that are in the tumor but were in the tumor but

“SMPAEDS1 is the largest study with mathed ctdna and tissue sequencing to date and shows the value of ctdna testing for children with cancer. CTDNA Analysis from Being a research test to being available clinically.

“The project also identifies dna mutations that become enriched at relapse. Cancers with that there mutations. “

The second phase of the research program, smpaeds2, is currently underway and aims to develop and study new tests that will build upon the success of the health. SMPAEDS2 will Investigate Blood Cancers and Solid Tumors in Children and Young People, Including in the Brain, Muscle and Bone, Which Can Be More DIFICULT TCECES, Diagnose and Treaty.

Children with Cancer Uk Ceo, Amar Naher Said, “We’re Proud to be involved in a research project leading the way in advance precision medicine in the uk. Every child and young person survives their cancer diagnosis.

“The outcomes from the SMPAEDS programs could help in the development of targeted treatment and old lead to improved, Less Invasive Ways of Monitoring and Monitoring and Treating Childhood Cancers. That Drive Relaps, The Project Helps Advance Personalized Treatments, Supporting The Charity’s Aims to Improve Survival Rates and Quality of Life for Young Cancer Patients. “

Dr. Laura Danielson, Children’s and Young People’s Research Lead at Cancer Research Uk, Said, “We’re Excited About This New Research from the Sampaeds Program Raveling Blood Tests to Better Undrstand Solid Tumors in Children and Young People.

“These data demonstrating that analyzing ctdna count lead to a more complete picture of the tumor and how it is changing over time are incredible. Or Lack of Response to Treatment, And With the Hope of Developing Better, More Targeted Treatments. Childhood cancers to give young cancer patients the best possible chance to live long, healthy lives. “